The Bill & Melinda Gates Foundation has made the payment of the second tranche of a grant to fund the second
formulation research phase of a best-in-class long acting contraceptive.
This payment is based on promising in vivo results that have been obtained during the first 12 months of the project and substantiates the feasibility potential
The Gates Foundation is supporting MedinCell to develop a product for women most in need in emerging countries.
MedinCell is evaluating ways to extract the product’s potential in developed countries, especially in the US where the contraceptive market is worth €4.7bn.
Following positive results of in vivo studies, the Bill & Melinda Gates Foundation has confirmed its support to pursue the formulation research of a 6-month active contraceptive. The objective is to enter non-clinical development in 2020 and then clinical development.
MedinCell has been awarded a $3.5m grant by the Bill & Melinda Gates Foundation to fund the formulation research
phase of this program. A first tranche of $2m was received at the start of the program in November 2017, and the
second of $1.5m has just been received following promising first in vivo results.
The product should be the first contraceptive to combine the following essential features that would make it a best-inclass product both in developing and developed countries.
• Progestin molecule (non-MPA)
• 6-month duration
• Subcutaneous injection
• Full bio-resorption
The Foundation aims at making the product available to most in need women in emerging countries.
The product could indeed address major challenges such as low affordability, weak distribution systems or cultural
barriers. Unlike most other Long-Acting Reversible Contraceptives (LARC) such as contraceptive implants, no surgical or specialist intervention will be necessary with the product of MedinCell. After a simple subcutaneous injection, a depot is formed that acts as a virtual-pump up for 6 months and then disappears completely.
Studies have shown that the risk of contraceptive failure for women using oral contraceptive pills or other methods is 17 to 20 times higher than the risk for those using LARCs mostly due to the lack of patient adherence to contraceptive treatments1.
MedinCell is evaluating ways to leverage the product’s potential in developed countries, especially in the US where
contraceptive market worth €4.7bn.
In 2017, LARCs represented 30% of the €4.7bn US contraceptive market with 10% 5 years-CAGR (mainly composed
of solid implants and intrauterine devices)2.
1. Winner, B; Peipert, JF; Zhao, Q; Buckel, C; Madden, T; Allsworth, JE; Secura, GM. (2012), “Effectiveness of Long-Acting Reversible Contraception”, New England Journal of
Medicine, 366 (21): 1998–2007, doi:10.1056/NEJMoa1110855, PMID 22621627
2. Source: IQVIA data in € at constant exchange rates in ex-manufacturer prices